Healthcare / Pharmaceutical RetailersTokyo
$3290.00
-20.00 (-0.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.2B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100.3B
P/E
12.8x
↓EV/EBITDA
7.8x
↓ROE
13.2%
↑Gross Margin
20.4%
↓Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
-1.3%
FCF / Net income
-0.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $200.79B · net income $7.07B · FCF $-2.51B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $200.79B | $200.79B | $184.86B | $169.06B | $154.64B |
| Net Income | $7.07B | $7.07B | $6.32B | $4.76B | $4.42B |
| EBITDA | $16.41B | $16.41B | $14.47B | $11.73B | $10.73B |
| EPS | 232.04 | 232.04 | 207.94 | 156.79 | 145.44 |
| Gross Margin | 20.4% | 20.4% | 20.4% | 20.4% | 20.0% |
| Operating Margin | 4.8% | 4.8% | 4.9% | 4.0% | 3.7% |
| Net Margin | 3.5% | 3.5% | 3.4% | 2.8% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.64 | 0.64 | 0.66 | 0.80 | 0.85 |
| Current Ratio | 0.94 | 0.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.51B | $-2.51B | $2.81B | $-1.16B | $-4.43B |
| Returns | |||||
| ROE | 13.2% | 13.2% | 13.5% | 11.7% | 12.2% |
| Valuation | |||||
| P/E | 12.84 | 12.84 | 13.36 | 12.93 | 11.45 |
| EV/EBITDA | 7.82 | 7.82 | 7.55 | 7.56 | 7.09 |
| P/B | 1.88 | 1.88 | 1.81 | 1.51 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | 9.3% | 9.3% | — |
| EPS Growth | 11.6% | 11.6% | 32.6% | 7.8% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.0%
EPS terminal req.
$291.93
Spread vs growth
3.6%
5Y implied EPS CAGR
8.8%
EPS terminal req.
$353.24
Spread vs growth
2.8%
10Y implied EPS CAGR
9.4%
EPS terminal req.
$568.89
Spread vs growth
2.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.0%
Start / end P/E
16.5x → 14.2x
EPS bridge
207.94 → 232.04
Residual
-1.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.